Show simple item record

The Ocular Gene Delivery Landscape

dc.contributor.authorSahu, Bhubanananda
dc.contributor.authorChug, Isha
dc.contributor.authorKhanna, Hemant
dc.date2022-08-11T08:10:01.000
dc.date.accessioned2022-08-23T16:52:31Z
dc.date.available2022-08-23T16:52:31Z
dc.date.issued2021-08-01
dc.date.submitted2022-02-15
dc.identifier.citation<p>Sahu B, Chug I, Khanna H. The Ocular Gene Delivery Landscape. Biomolecules. 2021 Aug 1;11(8):1135. doi: 10.3390/biom11081135. PMID: 34439800; PMCID: PMC8394578. <a href="https://doi.org/10.3390/biom11081135">Link to article on publisher's site</a></p>
dc.identifier.issn2218-273X (Linking)
dc.identifier.doi10.3390/biom11081135
dc.identifier.pmid34439800
dc.identifier.urihttp://hdl.handle.net/20.500.14038/42069
dc.description.abstractThe eye is at the forefront of developing therapies for genetic diseases. With the FDA approval of the first gene-therapy drug for a form of congenital blindness, numerous studies have been initiated to develop gene therapies for other forms of eye diseases. These examinations have revealed new information about the benefits as well as restrictions to using drug-delivery routes to the different parts of the eye. In this article, we will discuss a brief history of gene therapy and its importance to the eye and ocular delivery landscape that is currently being investigated, and provide insights into their advantages and disadvantages. Efficient delivery routes and vehicle are crucial for an effective, safe, and longer-lasting therapy.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34439800&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjecteye
dc.subjectgene therapy
dc.subjectretina
dc.subjectCongenital, Hereditary, and Neonatal Diseases and Abnormalities
dc.subjectEye Diseases
dc.subjectGenetics and Genomics
dc.subjectMolecular, Cellular, and Tissue Engineering
dc.subjectOphthalmology
dc.subjectTherapeutics
dc.titleThe Ocular Gene Delivery Landscape
dc.typeJournal Article
dc.source.journaltitleBiomolecules
dc.source.volume11
dc.source.issue8
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5905&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4872
dc.identifier.contextkey28209056
refterms.dateFOA2022-08-23T16:52:31Z
html.description.abstract<p>The eye is at the forefront of developing therapies for genetic diseases. With the FDA approval of the first gene-therapy drug for a form of congenital blindness, numerous studies have been initiated to develop gene therapies for other forms of eye diseases. These examinations have revealed new information about the benefits as well as restrictions to using drug-delivery routes to the different parts of the eye. In this article, we will discuss a brief history of gene therapy and its importance to the eye and ocular delivery landscape that is currently being investigated, and provide insights into their advantages and disadvantages. Efficient delivery routes and vehicle are crucial for an effective, safe, and longer-lasting therapy.</p>
dc.identifier.submissionpathoapubs/4872
dc.contributor.departmentDepartment of Ophthalmology and Visual Sciences
dc.source.pages1135


Files in this item

Thumbnail
Name:
biomolecules_11_01135.pdf
Size:
974.1Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).